H2UB is intended to be a Life Science infrastructure aimed at fostering new drug development through a network of laboratories capable of providing basic, translational and preclinical research support using cutting-edge technologies.
Governance of the Hub will be centralized and will provide support in regulatory, ethics and management, as well as organizational and dissemination. Expertise will be articulated in thematic platforms that will include:
basic research (biobanks of iPS and organoids as models of pathology; identification of specific molecular targets; fabrication of bio-electronic systems for drug evaluation);
pre-clinical research (animal models, identification and validation of disease biomarkers through computational data analysis, pharmacodynamics);
new drug development (manufacturing, safety monitoring, specificity and formulation);
clinical consulting.
H2UB meets the need to manage and develop research infrastructure of high complexity. Its value is measured not only in the list of resources and services made available but also as a space where researchers can be stimulated to improve the way they do research by providing expertise, technology, and managerial support.
CRS4 will contribute to the:
implementation and validation of innovative technology platforms for Drug Screening through the definition of genomic and epigenomic targets to be evaluated and the validation of results using genomic techniques;
study, development and implementation of flexible and scalable tools for computational pathology;
developing of molecular modeling tools, to be implemented in the computing platform, with reference to the druggability of molecules and potential drugs on specific therapeutic targets;
organization of training activities and schools on molecular modeling and metabolomics.
